Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse

@article{Oka2019ClinicalEO,
  title={Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse},
  author={Satoko Oka and Kazuo Ono and Masaharu Nohgawa},
  journal={Pathology & Oncology Research},
  year={2019},
  pages={1 - 8}
}
  • Satoko Oka, Kazuo Ono, Masaharu Nohgawa
  • Published in Pathology & Oncology Research 2019
  • Medicine, Biology
  • In the present study, we investigated the effects of immunophenotyping on prognosis of diffuse large B cell lymphoma (DLBCL) with central nervous system (CNS) relapse treated with rituximab-CHOP (R-CHOP). CNS relapse occurred in 9.5% of DLBCL patients. At the diagnosis of DLBCL, CD25 was detected in 14.3% of cases. CD25 positivity correlated with an advanced stage, higher R-IPI, higher CNS-IPI, the presence of B symptoms, the presence of extranodal involvement >1, and bone involvement. Moreover… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 34 REFERENCES

    CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.